Sugi Predict

Sugi Predict / Compounds / SCHEMBL2554955

SCHEMBL2554955

SCHEMBL2554955

CC(C)(C)OC(=O)NC1(c2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 4/20 0.47
▸ CNR1 P21554 2/20 0.45
▸ CNR2 P34972 2/20 0.45
▸ TSHR P16473 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SSTR4 P31391 1/20 0.43
▸ AKT2 P31751 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89721 0.94 SSTR4 (0.50) AKT1CNR1CNR2POLBSSTR4
SCHEMBL17040898 0.94 SSTR4 (0.47) AKT1CNR1CNR2TSHRALOX15
SCHEMBL3892253 0.91 OPRM1 (0.45) AKT1CNR1CNR2TSHRALOX15
SCHEMBL25156379 0.91 AKT1 (0.51) AKT1CNR1CNR2AKT2MEN1
Hydrochloric Acid SCHEMBL27552695 0.90 OPRM1 (0.44) AKT1CNR1CNR2TSHRALOX15
SCHEMBL1412064 0.90 CNR1 (0.44) AKT1CNR1CNR2TSHRALOX15
SCHEMBL16420447 0.89 CNR1 (0.47) AKT1CNR1CNR2TSHRALOX15
SCHEMBL25156540 0.89 AKT1 (0.45) AKT1CNR1CNR2AKT2MEN1
SCHEMBL15630929 0.88 HDAC4 (0.45) AKT1CNR1CNR2TSHRALOX15
SCHEMBL22090165 0.88 KMT2A (0.40) AKT1CNR1CNR2TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 — — CN disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
CN-104411684-B Phenoxyethyl piperidine compounds 伊莱利利公司 2016-08-24 — — CN disclosed
CN-105229006-A As piperazine and the homopiperazine derivative of HIV adsorption inhibitor BRISTOL MYERS SQUIBB CO 2016-01-06 — — CN disclosed
WO-2014160689-A9 PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-31 — — WO disclosed
WO-2014160689-A1 PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-02 — — WO disclosed
WO-2011123937-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2011-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 AKT1 102/4885CNR1 670/4885CNR2 543/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB AKT1 15/4885CNR1 2221/4885CNR2 2111/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB AKT1 15/4885CNR1 2221/4885CNR2 2111/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB AKT1 15/4885CNR1 2221/4885CNR2 2111/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB AKT1 15/4885CNR1 2221/4885CNR2 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.